Company profile: LumaCyte
1.1 - Company Overview
Company description
- Provider of label-free single-cell analysis solutions that accelerate medical discoveries, including Radiance, an instrument measuring cellular response using optical and fluidic forces; Laser Force Cytology technology; and software suites Illuminate for control/data analysis and ReportR for automated cloud reporting.
Products and services
- Laser Force Cytology (LFC): A label-free single-cell analysis technology that identifies and measures intrinsic cellular properties without antibodies or genetic labeling, enabling precise characterization of cells’ biophysical responses
- Radiance: A label-free single-cell analysis instrument that measures cellular response and changes using optical and fluidic forces, facilitating detailed assessment of individual cell behavior for research
- Illuminate: An instrument-control software suite designed for LumaCyte’s technology that manages instrument operation, performs data analysis, and executes data conversion for efficient laboratory workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LumaCyte
Advanced Analytical Technologies
HQ: United States
Website
- Description: Provider of high-throughput, fully-automated nucleic acid and genetic analysis systems for commercial and research applications, designed to improve processes in the molecular diagnostics, pharmaceutical, life science, agricultural, and biofuels industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Analytical Technologies company profile →
Advicenne
HQ: France
Website
- Description: Provider of specialty pharmaceutical treatments targeting rare kidney diseases, developing and commercializing therapies in nephrology. Portfolio includes Sibnayal for distal renal tubular acidosis (dRTA); licensed medications Likozam (clobazam) and Levidcen (levetiracetam) in France; and ADV7103, an experimental late-stage therapy for dRTA and cystinuria in children and adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advicenne company profile →
Miromatrix
HQ: United States
Website
- Description: Provider of fully biological human organs and organ-derived products to address the transplant shortage, using patented perfusion decellularization/recellularization technology, plus PAH therapy and patient support via Remodulin (IV/SC), ASSIST, Archways for inhaled/oral treprostinil, and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miromatrix company profile →
Crawford Scientific
HQ: United Kingdom
Website
- Description: Provider of chromatography consumables and products (columns, vials, syringe filters, gas generators), analytical services, and chromatography/mass spectrometry training, offering HPLC columns, technical support and consultancy, online training courses, and the CHROMacademy eLearning platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crawford Scientific company profile →
Champions Oncology
HQ: United States
Website
- Description: Provider of advanced technology solutions and services for personalizing the development and use of oncology drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Champions Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LumaCyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LumaCyte
2.2 - Growth funds investing in similar companies to LumaCyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LumaCyte
4.2 - Public trading comparable groups for LumaCyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →